Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Q2 2024 Earnings Conference Call August 1, 2024 11:30 AM ET Company Participants Wade Walke - Senior Vice President of Investor Relations Brett Monia - Chief Executive Officer Richard Geary - Executive Vice President and Chief Development Officer Kyle Jenne - Executive Vice President and Chief Global Product Strategy Officer Elizabeth Hougen - Executive Vice President and Chief Financial Officer Eric Swayze - Executive Vice President of Research Eugene Schneider - E ...

Exhibit 99.1 Ionis reports second quarter 2024 financial results WAINUATM U.S. launch progressing well; approved in Canada; EU approval decision expected this year Olezarsen PDUFA December 19, 2024 for FCS Positive Phase 3 donidalorsen data for HAE; preparing U.S. and EU regulatory submissions On track to achieve 2024 financial guidance CARLSBAD, Calif., August 1, 2024 – Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) (the "Company"), today reported financial results for the second quarter of 2024. "Over the fir ...

For the quarter ended June 2024, Ionis Pharmaceuticals (IONS) reported revenue of $225 million, up 19.7% over the same period last year. EPS came in at -$0.45, compared to -$0.60 in the year-ago quarter. The reported revenue represents a surprise of +52.56% over the Zacks Consensus Estimate of $147.49 million. With the consensus EPS estimate being -$0.95, the EPS surprise was +52.63%. While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to ...

Ionis Pharmaceuticals (IONS) came out with a quarterly loss of $0.45 per share versus the Zacks Consensus Estimate of a loss of $0.95. This compares to loss of $0.60 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 52.63%. A quarter ago, it was expected that this drug discovery and development company would post a loss of $1.10 per share when it actually produced a loss of $0.98, delivering a surprise of 10.91%. Over the last ...

WAINUATM U.S. launch progressing well; approved in Canada; EU approval decision expected this year Three months ended Six months ended Olezarsen PDUFA December 19, 2024 for FCS Positive Phase 3 donidalorsen data for HAE; preparing U.S. and EU regulatory submissions On track to achieve 2024 financial guidance CARLSBAD, Calif., Aug. 1, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) (the "Company"), today reported financial results for the second quarter of 2024. "Over the first half of this y ...

Ionis Pharmaceuticals (IONS) is expected to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended June 2024. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price. The earnings report, which is expected to be released on August 1, 2024, might help the stock move higher if these key numbers are better ...

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) HALOS Study of ION582 in Angelman Syndrome Conference Call July 22, 2024 8:00 AM ET Company Participants Wade Walke - Senior Vice President of Investor Relations Brett Monia - Chief Executive Officer Holly Kordasiewicz - Senior Vice President, Neurology Elizabeth Jalazo - Assistant Professor of Pediatrics, Division of Genetics & Metabolism, University of North Carolina School of Medicine Becky Crean - Executive Director, Neurology Lynne Bird - Professor of Clinical ...

Loading... Ionis Pharmaceuticals Inc IONS released results Monday from the completed multiple ascending dose (MAD) portion of the Phase 1/2 open-label study of ION582 in people with Angelman syndrome (AS). AS is a rare neurodevelopmental disorder caused by a loss of function in the maternal UBE3A gene. It affects an estimated 1 in 21,000 people worldwide. The data demonstrated consistent and encouraging clinical improvement on assessing all functional domains, including communication, cognition, and motor f ...

ION582 showed robust and consistent benefit in communication, cognition and motor function in a broad patient population evaluated with a comprehensive set of assessment tools that collect input from parents and clinicians 97% of patients in the medium and high dose groups saw improvement in overall Angelman syndrome symptoms as measured by the SAS-CGI-C Improvements on the Bayley-4 in cognition, communication and motor function exceeded those observed in natural history studies Ionis plans to initiate Phas ...

Though IONS did not specify the total number of patients enrolled in the study, a government website states that the study has a target enrolment of nearly 73 study participants aged between two to 65 with AxD across eight countries. AxD is a rare neurological disease that affects a type of cell in the brain called astrocytes, which have multiple roles in the brain to support neurons and oligodendrocytes. People living with this condition are marked by cognitive dysfunction and progressive neurologic deteri ...